췌장암의 gemcitabine 치료를 향상시키기 위해 초음파와 마이크로버블을 이용한 임상시험에 관한 리뷰

요약문 The combined therapeutic regimen did not induce any additional toxicity or increased frequency of side effects tolerated an increased number of gemcitabine cycles(n = 63 patients; average of 8.3±6.0 cycles, versus 13.8±5.6 cycles, p=0.008, unpaired t test). the maximum tumour diameter was decreased(5명) The median survival in our patients (n = 10) was also increased from 8.9 months to 17.6 months.(p=0.011) DOI: 10.1016/j.jconrel.2016.10.007